🔉 Did tinnitus loudness improve?
None shown.
No drug has shown a loudness effect in a confirmatory trial.
Off-label oral drugs (antidepressants, benzodiazepines, gabapentin, betahistine) for Tinnitus: What Does the Evidence Show?
Drugs & Pharmacology
Current evidence
No drug has an FDA-approved indication for tinnitus — and the systematic reviews say none of the usual suspects works on the tinnitus itself.
Evidence strength: Weak (1/5) · Tier 5 — weak or unsupported · Evidence independence: Primarily independent.
Commonly prescribed medications used off-label: tricyclics/SSRIs, benzodiazepines, anticonvulsants (gabapentin), betahistine and others. There is no FDA- or EMA-approved drug for tinnitus.
Did tinnitus loudness or distress improve?
🧠 Did tinnitus distress improve?
Limited.
Antidepressants can help comorbid depression/anxiety; Cochrane finds tricyclics no better than placebo for tinnitus severity; insufficient evidence for benzodiazepines; gabapentin ineffective; betahistine — 'absence of evidence'.
Loudness means the tinnitus percept itself became quieter (psychoacoustic matching or loudness ratings). Distress means questionnaire scores such as THI/TFI, sleep, anxiety or quality of life improved — the sound may be unchanged. A THI/TFI improvement is never evidence the tinnitus got quieter.
How strong is the evidence?
Half a century of trials without a single confirmatory win: 1/5 for tinnitus itself (comorbidity treatment is a separate, legitimate decision).
What the studies found 8 tracked
Pharmacotherapy for subjective tinnitus: network meta-analysis of 60 RCTs
Li P, Che C, Wu Y, et al. · BMJ Open · 2025 · N=60 RCTs · Systematic review + network meta-analysis (>30 drug interventions)
No approved drug exists; 78% of included studies had methodological concerns; evidence quality low to very low. Tentative signals (antioxidants, GABA agonists) are hypothesis-generating only and conflict with Cochrane.
Betahistine for tinnitus (Cochrane Review)
Wegner I, et al. · Cochrane Database of Systematic Reviews · 2018 · N=5 studies, N≈305 · Systematic review
'Absence of evidence' of any effect on subjective idiopathic tinnitus vs placebo; well tolerated.
QUIET-1: AUT00063 (Kv3 modulator) Phase 2a — stopped early for futility
Hall DA, Ray J, Watson J, et al. · Hearing Research · 2019 · N=91 · Randomized placebo-controlled Phase 2a
Stopped early for futility after a planned interim analysis (91 of a planned 152 randomised; 76 in the primary analysis). TFI change −1.6 points in the AUT00063 arm vs −5.8 with placebo (p = 0.98) — no benefit despite drug exposure in the expected therapeutic range.
Cochrane: antidepressants for tinnitus (CD003853)
Baldo P, et al. · Cochrane Database of Systematic Reviews · 2012 · N=6 trials, 610 patients · Cochrane systematic review
Verbatim conclusion: 'There is as yet insufficient evidence to say that antidepressant drug therapy improves tinnitus.'
Distinct from treating comorbid depression, which can itself be worthwhile.
Neramexane for tinnitus: Phase 2 miss and unpublished Phase 3 program
Suckfüll M, et al. (Phase 2); Merz Pharmaceuticals (Phase 3 program) · BMC Ear, Nose and Throat Disorders (Phase 2) · 2011 · N=Phase 2: 431; Phase 3 program: NCT00739635 (411), NCT00772980 (400), NCT00955799 (455) · Phase 2 randomized placebo-controlled dose-ranging; three completed Phase 3 RCTs (no journal publication found; results posted on the EU register)
Phase 2: primary endpoint NOT met at any dose (50 mg p=0.098). The three Phase 3 trials completed ~2010–2011; no journal publication of their efficacy results was found (the EU Clinical Trials Register posts results for several of the Merz neramexane tinnitus trials, first posted December 2016); the open-label extension was terminated (Dec 2011) and the program abandoned.
A cautionary publication-bias case: no journal publication of the Phase 3 efficacy results was found. The EU Clinical Trials Register posts results for several Merz neramexane trials, and the Emerging section reports no difference from placebo in the one Phase III result it read there; those figures have not yet been extracted into this record, so the rating rests on the non-publication, the terminated extension and the abandoned program.
Gabapentin for tinnitus: randomized double-blind trial (negative)
Piccirillo JF, et al. · Archives of Otolaryngology–Head & Neck Surgery · 2007 · N=115 analyzed (59 gabapentin / 56 placebo) · 8-week randomized double-blind placebo-controlled trial (900–3600 mg/day)
NEGATIVE: THI improved 11.3 vs 11.0 points — difference 0.03 [95% CI −5.5, 6.2], p=.91. 'Gabapentin is no more effective than placebo.'
Both arms improved equally — a clean demonstration of the placebo/natural-course response that uncontrolled tinnitus studies mistake for efficacy.
Cochrane: anticonvulsants for tinnitus (CD007960)
Hoekstra CE, et al. · Cochrane Database of Systematic Reviews · 2011 · N=7 RCTs, 453 patients · Cochrane systematic review
No evidence of a large positive effect; a small effect 'of doubtful clinical significance' was demonstrated, with significant risk of bias.
AAO-HNSF Clinical Practice Guideline: Tinnitus
Tunkel DE, Bauer CA, Sun GH, et al. · Otolaryngology–Head and Neck Surgery · 2014 · N=Guideline (23-author multidisciplinary panel) · Clinical practice guideline (US)
RECOMMENDS: hearing-aid evaluation (with hearing loss) and CBT for persistent bothersome tinnitus. OPTION: sound therapy ('may recommend'). AGAINST routine use: medical therapy (antidepressants, anticonvulsants, anxiolytics, intratympanic drugs), dietary supplements (Ginkgo, melatonin, zinc), and rTMS. NO RECOMMENDATION: acupuncture.
Guidelines are consensus documents, not new trial data. Where the three major guidelines disagree — chiefly on sound therapy (AAO-HNSF: option; NICE and the European guideline: research-only; the German S3 guideline: against sound generators) — this platform shows the disagreement rather than picking a side. Statement strengths read from the published abstracts; full-text verbatim wording not independently re-read.
What are the limitations?
- 2025 network meta-analysis: 78% of drug trials have methodological concerns; evidence low to very low
Has the result been independently replicated?
None yet.
What should patients know about safety?
Safety evidence: Limited. Real side-effect burdens — benzodiazepine dependence, anticholinergic effects, sedation. Weigh against absent tinnitus benefit. Do not stop a benzodiazepine suddenly or lower the dose quickly: the FDA warns this can cause withdrawal reactions, including seizures, that can be life-threatening. Talk to the prescriber before any change.
Is it available?
Regulatory status: No FDA-approved drug for tinnitus (use is off-label). AAO-HNSF 2014 recommends against routine antidepressants, anticonvulsants, anxiolytics and intratympanic drugs for tinnitus. A few drugs are licensed for tinnitus in other countries (Stomin A in Japan; caroverine in India, approved 2006), but the evidence that they work is limited or inconsistent.
Availability: Prescription, off-label · Europe: Same (betahistine widely used for vertigo) · Cost (approx.): Generic pricing
Related clinical trials 1
Tracked trials are research in progress, not recommended treatments.
Related treatments 4
- SPI-1005 (ebselen) — The most advanced drug with a tinnitus-relevant claim — but its trials are in Meniere's disease, and the…
- TRTL-913 (GABA-A modulator) — A new $106M bet that a GABA-A drug can quiet tinnitus — Phase 2 starts soon; no human tinnitus data yet.
- Intratympanic drug injections — Injections through the eardrum keep failing their controlled tests: the experimental drugs did not beat…
- Supplements (ginkgo, zinc, melatonin…) — Heavily marketed, repeatedly tested — and rigorous reviews have found no reliable benefit.
Evidence last reviewed: 2026-09-04 · Evidence included through: 2026-09-04 · Confidence: high. Open the interactive evidence profile · How we rate evidence.
This page summarizes published research for education. It is not medical advice; it cannot say what will work for any individual. Discuss treatment decisions with a qualified clinician.